Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME database

In France, 40% of patients diagnosed with lung cancer are ≥70 years old, but these are under-represented in clinical trials. Using data from the French Epidemiological Strategy and Medical Economics (ESME) platform on Lung Cancer (LC), the objective is to provide an overview of the management and th...

Full description

Saved in:
Bibliographic Details
Published in:Journal of geriatric oncology 2024-09, Vol.15 (7), p.101819, Article 101819
Main Authors: Cabart, Mathilde, Mourey, Loïc, Pasquier, David, Schneider, Sophie, Léna, Hervé, Girard, Nicolas, Chouaid, Christos, Schott, Roland, Hiret, Sandrine, Debieuvre, Didier, Quantin, Xavier, Madroszyk, Anne, Dubray-Longeras, Pascale, Pichon, Eric, Baranzelli, Anne, Justeau, Grégoire, Pérol, Maurice, Bosquet, Lise, Cabarrou, Bastien
Format: Article
Language:English
Subjects:
Age Factors
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - mortality
Carcinoma, Non-Small-Cell Lung - pathology
Carcinoma, Non-Small-Cell Lung - therapy
Chemotherapy
Databases, Factual
EGFR mutation
Female
France - epidemiology
Humans
Immunotherapy
Lung Neoplasms - drug therapy
Lung Neoplasms - mortality
Lung Neoplasms - pathology
Lung Neoplasms - therapy
Male
Middle Aged
Non-small cell lung cancer
Older patients
Pattern of care
Prognosis
Progression-Free Survival
Targeted therapy
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In France, 40% of patients diagnosed with lung cancer are ≥70 years old, but these are under-represented in clinical trials. Using data from the French Epidemiological Strategy and Medical Economics (ESME) platform on Lung Cancer (LC), the objective is to provide an overview of the management and the prognosis of older patients with advanced or metastatic non-small cell lung cancer (AM-NSCLC) in a real-world context. From the ESME-LC database, we selected patients with AM-NSCLC (stage IIIB, IIIC, and IV), diagnosed between 2015 and 2019, and who received first-line systemic treatment. Demographics, tumour characteristics, and treatment received were described in patients ≥70, and compared to younger ones. Real-world progression-free survival (rwPFS) and overall survival (OS) were evaluated using the multivariable Cox model. Among 10,002 patients with AM-NSCLC, the median age was 64 years, with 2,754 (27.5%) aged ≥70. In comparison with patients
ISSN:1879-4068
1879-4076
1879-4076
DOI:10.1016/j.jgo.2024.101819